Relay Therapeutics
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Relay Therapeutics generated cash of -$300,316,000, which is less than the previous year. Cash used in financing activities reached the amount of $34,753,000 last year. Net change in cash is therefore -$7,929,000.
Cash Flow
| 2018 | -44.13M | -1.68M | 394.97M |
|---|---|---|---|
| 2019 | -66.13M | -319.02M | 5.60M |
| 2020 | -102.48M | 81.67M | 426.50M |
| 2021 | -74.40M | -479.51M | 388.09M |
| 2022 | -229.49M | -188.74M | 289.91M |
| 2023 | -300.31M | 257.63M | 34.75M |
RLAY Cash Flow Statement (2018 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
Cash at beginning of period | 154.37M | 282.69M | 448.52M | 42.83M | 422.38M | 73.22M |
Operating activities | ||||||
Net income | -341.97M | -290.50M | -363.87M | -52.41M | -75.30M | -48.78M |
| Adjustments to reconcile net income to cash generated by operating activities: | ||||||
Depreciation and amortization | 5.26M | 4.13M | 3.92M | 3.54M | 2.84M | 2.15M |
Stock-based compensation expense | 86.03M | 56.13M | 48.45M | 31.96M | 4.45M | 2.88M |
| Deferred income tax benefit | 86.03M | 56.13M | 48.45M | 31.96M | 4.45M | 2.88M |
| Changes in operating assets and liabilities: | ||||||
Accounts receivable, net | 0 | 97K | 74.67M | -75M | 0 | 0 |
Inventories | 0 | 0 | 21.46M | -10.33M | 0 | 0 |
Accounts payable | -2.39M | 1.98M | 930K | -410K | 3M | 1.23M |
Cash generated by operating activities | -300.31M | -229.49M | -74.40M | -102.48M | -66.13M | -44.13M |
Investing activities | ||||||
Purchases Of Investments | -385.54M | -535.41M | -980.66M | -266.45M | -553.51M | 0 |
Investments In Property Plant And Equipment | -4.12M | -9.06M | -3.47M | -1.93M | -8.00M | -1.68M |
Acquisitions Net | 0 | 179.68M | -25.29M | -83.60M | 20K | 0 |
Cash generated by investing activities | 257.63M | -188.74M | -479.51M | 81.67M | -319.02M | -1.68M |
Financing activities | ||||||
Common Stock Issued | 30.28M | 284.74M | 382.21M | 427.8M | 613K | 0 |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 34.75M | 289.91M | 388.09M | 426.50M | 5.60M | 394.97M |
Net Change In Cash | -7.92M | -128.32M | -165.82M | 405.69M | -379.55M | 349.15M |
Cash at end of period | 146.44M | 154.37M | 282.69M | 448.52M | 42.83M | 422.38M |
| Data source | Data source | Data source | Data source |